Literature DB >> 18261756

Vaccination of rhesus macaques with a vif-deleted simian immunodeficiency virus proviral DNA vaccine.

Ellen E Sparger1, Robert A Dubie, Barbara L Shacklett, Kelly S Cole, W L Chang, Paul A Luciw.   

Abstract

Studies in non-human primates, with simian immunodeficiency virus (SIV) and simian/human immunodeficiency virus (SHIV) have demonstrated that live-attenuated viral vaccines are highly effective; however these vaccine viruses maintain a low level of pathogenicity. Lentivirus attenuation associated with deletion of the viral vif gene carries a significantly reduced risk for pathogenicity, while retaining the potential for virus replication of low magnitude in the host. This report describes a vif-deleted simian immunodeficiency virus (SIV)mac239 provirus that was tested as an attenuated proviral DNA vaccine by inoculation of female rhesus macaques. SIV-specific interferon-gamma enzyme-linked immunospot responses of low magnitude were observed after immunization with plasmid containing the vif-deleted SIV provirus. However, vaccinated animals displayed strong sustained virus-specific T cell proliferative responses and increasing antiviral antibody titers. These immune responses suggested either persistent vaccine plasmid expression or low level replication of vif-deleted SIV in the host. Immunized and unvaccinated macaques received a single high dose vaginal challenge with pathogenic SIVmac251. A transient suppression of challenge virus load and a greater median survival time was observed for vaccinated animals. However, virus loads for vaccinated and unvaccinated macaques were comparable by twenty weeks after challenge and overall survival curves for the two groups were not significantly different. Thus, a vif-deleted SIVmac239 proviral DNA vaccine is immunogenic and capable of inducing a transient suppression of pathogenic challenge virus, despite severe attenuation of the vaccine virus.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18261756      PMCID: PMC2519864          DOI: 10.1016/j.virol.2008.01.020

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  52 in total

1.  Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251.

Authors:  Barbara L Shacklett; Karen E S Shaw; Lou A Adamson; David T Wilkens; Catherine A Cox; David C Montefiori; Murray B Gardner; Pierre Sonigo; Paul A Luciw
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  HIV preferentially infects HIV-specific CD4+ T cells.

Authors:  Daniel C Douek; Jason M Brenchley; Michael R Betts; David R Ambrozak; Brenna J Hill; Yukari Okamoto; Joseph P Casazza; Janaki Kuruppu; Kevin Kunstman; Steven Wolinsky; Zvi Grossman; Mark Dybul; Annette Oxenius; David A Price; Mark Connors; Richard A Koup
Journal:  Nature       Date:  2002-05-02       Impact factor: 49.962

3.  Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses.

Authors:  Kristina Abel; Lara Compton; Tracy Rourke; David Montefiori; Ding Lu; Kristina Rothaeusler; Linda Fritts; Kristen Bost; Christopher J Miller
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

4.  Titration of an SIVmac251 stock by vaginal inoculation of Indian and Chinese origin rhesus macaques: transmission efficiency, viral loads, and antibody responses.

Authors:  M L Marthas; D Lu; M C Penedo; A G Hendrickx; C J Miller
Journal:  AIDS Res Hum Retroviruses       Date:  2001-10-10       Impact factor: 2.205

5.  The vif gene of maedi-visna virus is essential for infectivity in vivo and in vitro.

Authors:  Helga Bryndís Kristbjörnsdóttir; Valgerdur Andrésdóttir; Vilhjálmur Svansson; Sigurbjörg Torsteinsdóttir; Sigrídur Matthíasdóttir; Olafur S Andrésson
Journal:  Virology       Date:  2004-01-05       Impact factor: 3.616

6.  Analysis of HIV-1- and CMV-specific memory CD4 T-cell responses during primary and chronic infection.

Authors:  Alexandre Harari; G Paolo Rizzardi; Kim Ellefsen; Donatella Ciuffreda; Patrick Champagne; Pierre-Alexandre Bart; Daniel Kaufmann; Amalio Telenti; Roland Sahli; Giuseppe Tambussi; Laurent Kaiser; Adriano Lazzarin; Luc Perrin; Giuseppe Pantaleo
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

7.  Presentation of exogenous whole inactivated simian immunodeficiency virus by mature dendritic cells induces CD4+ and CD8+ T-cell responses.

Authors:  Ines Frank; John J Santos; Erin Mehlhop; Loreley Villamide-Herrera; Christine Santisteban; Agegnehu Gettie; Ralf Ignatius; Jeffrey D Lifson; Melissa Pope
Journal:  J Acquir Immune Defic Syndr       Date:  2003-09-01       Impact factor: 3.731

8.  T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis.

Authors:  Jason M Brenchley; Brenna J Hill; David R Ambrozak; David A Price; Francisco J Guenaga; Joseph P Casazza; Janaki Kuruppu; Javaidia Yazdani; Stephen A Migueles; Mark Connors; Mario Roederer; Daniel C Douek; Richard A Koup
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

9.  Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses.

Authors:  David H O'Connor; Bianca R Mothe; Jason T Weinfurter; Sarah Fuenger; William M Rehrauer; Peicheng Jing; Richard R Rudersdorf; Max E Liebl; Kendall Krebs; Joshua Vasquez; Elizabeth Dodds; John Loffredo; Sarah Martin; Adrian B McDermott; Todd M Allen; Chenxi Wang; G G Doxiadis; David C Montefiori; Austin Hughes; Dennis R Burton; David B Allison; Steven M Wolinsky; Ronald Bontrop; Louis J Picker; David I Watkins
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

10.  Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation.

Authors:  Regina Hofmann-Lehmann; Josef Vlasak; Alison L Williams; Agnès-Laurence Chenine; Harold M McClure; Daniel C Anderson; Shawn O'Neil; Ruth M Ruprecht
Journal:  AIDS       Date:  2003-01-24       Impact factor: 4.177

View more
  4 in total

Review 1.  Use of nonhuman primate models to develop mucosal AIDS vaccines.

Authors:  Meritxell Genescà; Christopher J Miller
Journal:  Curr HIV/AIDS Rep       Date:  2010-02       Impact factor: 5.071

2.  Vaccination with vif-deleted feline immunodeficiency virus provirus, GM-CSF, and TNF-alpha plasmids preserves global CD4 T lymphocyte function after challenge with FIV.

Authors:  Saipiroon Maksaereekul; Robert A Dubie; Xiaoying Shen; Hung Kieu; Gregg A Dean; Ellen E Sparger
Journal:  Vaccine       Date:  2009-04-17       Impact factor: 3.641

3.  Co-immunization with IL-15 enhances cellular immune responses induced by a vif-deleted simian immunodeficiency virus proviral DNA vaccine and confers partial protection against vaginal challenge with SIVmac251.

Authors:  Robert A Dubie; Saipiroon Maksaereekul; Barbara L Shacklett; Donna Lemongello; Kelly S Cole; Francois Villinger; Shelley A Blozis; Paul A Luciw; Ellen E Sparger
Journal:  Virology       Date:  2009-02-03       Impact factor: 3.616

Review 4.  Immunization against small ruminant lentiviruses.

Authors:  Ramsés Reina; Damián de Andrés; Beatriz Amorena
Journal:  Viruses       Date:  2013-08-02       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.